|
|
||||||||||
|
J Am Coll Cardiol, 2004; 44:528-537, doi:10.1016/j.jacc.2004.03.077 © 2004 by the American College of Cardiology Foundation |









* Erasmus Medical Center, Rotterdam, The Netherlands
Onze Lieve Vrouw Ziekenhuis, Aalst, Belgium
UZ Gasthuisberg, Leuven, Belgium
Academisch Ziekenhuis Middelheim, Antwerpen, Belgium
|| Universitätsklinik Charité, Berlin, Germany
¶ Allgemeines Krankenhaus der Stadt, Wien, Austria
# Hospital Clínico San Carlos, Madrid, Spain
** CHR de la Citadelle, Liege, Belgium

Guidant, Diegem, Belgium

Cardialysis BV, Rotterdam, The Netherlands
Manuscript received November 21, 2003; revised manuscript received March 1, 2004, accepted March 2, 2004.
* Reprint requests and correspondence: Professor Patrick W. Serruys, Erasmus Medical Center, Thoraxcenter, Bd-406, Dr. Molewaterplein 40, 3015 GD, Rotterdam, The Netherlands.
p.w.j.c.serruys{at}erasmusmc.nl
OBJECTIVES: We sought to assess the efficacy of vascular brachytherapy (VBT) combined with stenting for the primary prevention of restenosis.
BACKGROUND: Intravascular brachytherapy after stent implantation for de novo lesions has been abandoned for the present. We revisited this procedure by optimizing all procedural stepsthe use of glycoprotein IIb/IIIa blockers, direct stenting, adequate radiation coverage, avoidance of edge damage, source centering, intravascular ultrasound-guided dosimetry, and continuation of a dual anti-platelet regimen for one year.
METHODS: The Beta-Radiation Investigation with Direct stenting and Galileo in Europe (BRIDGE) study is a multicenter, randomized controlled trial evaluating the long-term efficacy of VBT with P-32 (20 Gy at 1 mm in the coronary wall) after direct stenting. The primary end point was angiographic intra-stent late loss; secondary end points were six months binary restenosis and neo-intimal hyperplasia. Patients (n = 112) with de novo lesions (2.5 to 4.0 mm in diameter up to 15 mm long) were randomized to either VBT or no-VBT.
RESULTS: At six months, intra-stent loss was 0.43 and 0.84 mm (p < 0.001) in the irradiated and control groups, respectively. Intra-stent neo-intimal volume was reduced from 36 mm3 to 10 mm3. However, in the irradiated group there were six late occlusions as well as eight restenoses outside the stented and peri-stented area at the fall-off dose edges of the irradiated area. Accordingly, the target vessel revascularization and major adverse cardiac and cerebrovascular events rates at one year in the VBT group (20.4% and 25.9%, respectively) were higher than in the control group (12.1% and 17.2%, respectively).
CONCLUSIONS: Despite the optimization of pre-, peri-, and post-procedural factors and despite the relative efficacy of the brachytherapy for the prevention of the intra-stent neo-intimal hyperplasia, the clinical outcome of the irradiated group was less favorable than that of the control group.
| ||||||||||||||||||
This article has been cited by other articles:
![]() |
J. M. Wilson and J. T. Willerson Myocardial Revascularization with Percutaneous Devices Card. Surg. Adult, January 1, 2008; 3(2008): 573 - 598. [Full Text] |
||||
![]() |
E. Camenzind, P. G. Steg, and W. Wijns A Cause for Concern Circulation, March 20, 2007; 115(11): 1440 - 1455. [Full Text] [PDF] |
||||
![]() |
J. C.J. Sun, J. W. Eikelboom, P. Agostoni, G. M. Sangiorgi, G. G. Biondi-Zoccai, B. Scheller, M. Bohm, and E. Camenzind Treatment of Restenosis with a Paclitaxel-Coated Balloon Catheter N. Engl. J. Med., March 8, 2007; 356(10): 1071 - 1073. [Full Text] [PDF] |
||||
![]() |
W. W. O'Neill, S. R. Dixon, and C. L. Grines The year in interventional cardiology J. Am. Coll. Cardiol., April 5, 2005; 45(7): 1117 - 1134. [Full Text] [PDF] |
||||
![]() |
REFERENCES J. ICRU, December 1, 2004; 4(2): 165 - 175. [Full Text] [PDF] |
||||
| HOME | SUBSCRIPTIONS | CURRENT ISSUE | PAST ISSUES | CARDIOSOURCE | SEARCH | HELP | FEEDBACK |